Peapod Lane Capital LLC Invests $1.10 Million in Nkarta, Inc. (NASDAQ:NKTX)

Peapod Lane Capital LLC acquired a new position in Nkarta, Inc. (NASDAQ:NKTX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 598,245 shares of the company's stock, valued at approximately $1,101,000. Nkarta accounts for approximately 1.2% of Peapod Lane Capital LLC's portfolio, making the stock its 29th largest holding. Peapod Lane Capital LLC owned about 0.84% of Nkarta at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of NKTX. Sequoia Financial Advisors LLC purchased a new position in shares of Nkarta in the fourth quarter worth approximately $31,000. Thrivent Financial for Lutherans bought a new position in Nkarta in the fourth quarter worth approximately $258,000. American Century Companies Inc. boosted its stake in shares of Nkarta by 8.8% during the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock worth $226,000 after acquiring an additional 7,378 shares during the last quarter. Sei Investments Co. bought a new stake in shares of Nkarta during the 4th quarter valued at $57,000. Finally, Samalin Investment Counsel LLC purchased a new stake in shares of Nkarta in the 4th quarter worth $211,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Nkarta Stock Down 0.3%

Shares of NASDAQ NKTX traded down $0.01 during midday trading on Friday, reaching $1.80. 525,336 shares of the stock were exchanged, compared to its average volume of 1,028,743. The firm has a market cap of $127.37 million, a price-to-earnings ratio of -1.19 and a beta of 0.70. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $8.23. The firm has a 50-day simple moving average of $1.81 and a two-hundred day simple moving average of $1.95.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. Research analysts expect that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

NKTX has been the subject of several recent research reports. William Blair reissued a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Nkarta in a report on Thursday, March 27th. Stifel Nicolaus dropped their price target on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 27th. Mizuho dropped their price target on shares of Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday, June 10th. Finally, Needham & Company LLC lowered their target price on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, May 15th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $14.33.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.